FDA Approves ARGATROBAN — Hikma Pharmaceuticals USA Inc.

Hikma Pharmaceuticals USA Inc. received FDA approval for its intravenous ARGATROBAN application in January 2012, broadening its product portfolio of anticoagulants and strengthening its capabilities within the U.S. market. Hikma secured FDA approval for intravenous ARGATROBAN in January 2012 to enhance its hematology portfolio, positioning the company to capitalize on increased demand for anticoagulant therapies in the competitive U.S. marketplace.